Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

theramex ireland ltd. - estradiol hemihydrate 1,5 mg (component 1); levonorgestrel 1,5 mg (component 2); estradiol hemihydrate 1,5 mg (component 2) - transdermal patch - 50 µg/24 h - 10 µg/24 h - estradiol hemihydrate 1.5 mg; estradiol hemihydrate 1.5 mg; levonorgestrel 1.5 mg - levonorgestrel and estrogen

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

merck serono limited - estradiol hemihydrate levonorgestrel - transdermal patch - 50/7 microgram/day

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

merck serono limited - estradiol hemihydrate levonorgestrel - transdermal patch - microgram

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 10.3 microgram (equivalent: estradiol, qty 10 microgram) - pessary, modified release - excipient ingredients: macrogol 6000; magnesium stearate; lactose monohydrate; hypromellose; maize starch - vagifem low is indicated for the treatment of atrophic vaginitis due to oestrogen deficiency. vagifem low is not intended for children or males.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

besins healthcare sa-nv - estradiol hemihydrate 0,775 mg/dose - eq. estradiol 0,75 mg/dose - transdermal gel - 0,75 mg/dose - estradiol hemihydrate 0.775 mg/dose - estradiol

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - nomegestrol acetate, quantity: 2.5 mg; estradiol hemihydrate, quantity: 1.55 mg (equivalent: estradiol, qty 1.5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; purified talc; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - oral contraception.

Estats Units - anglès - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.025 mg in 1 d - estradiol transdermal system (twice-weekly) is indicated for:       when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products.       when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol transdermal system (twice-weekly) is contraindicated in women with any of the following conditions: estradiol transdermal system (twice-weekly) is not indicated for use in pregnancy. there are no data with the use of estradiol transdermal system (twice-weekly) in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregna

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg); norethisterone acetate, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hyprolose; purified talc; magnesium stearate; hypromellose; triacetin - short term symptomatic treatment of oestrogen deficiency associated with natural or artificial menopause (see dosage and administration and clinical trials).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.